6-bromo-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl 1-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate | 1426331-49-8

• 分子结构分类: 有机化合物
• 英文名称: 6-bromo-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl 1-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate
• 英文别名: (6-bromo-1-oxo-3,4-dihydro-2H-naphthalen-2-yl) 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylate
• CAS: 1426331-49-8
• 化学式: C₂₂H₂₈BrNO₅
• 分子量: 466.372
• InChiKey: ANANGNZZYVLYSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：LUPIN LTD

  公开号：WO2013030750A1

  公开（公告）日：2013-03-07

  Compounds of the general formula (I), their tautomeric forms, their stereoisomers, their analogs, their prodrugs, their isotopes, their N-oxides, their metabolites, their pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as antiviral candidate, more specifically as anti-HCV are disclosed.

  本发明公开了一般式（I）的化合物，它们的互变异构体，立体异构体，类似物，前药，同位素，N-氧化物，代谢物，药学上可接受的盐，多晶体，溶剂合物，光学异构体，笼合物，与适当药物的组合，含有它们的制药组合物，上述化合物的制备方法，以及它们作为抗病毒候选物，更具体地作为抗HCV的用途。
• [EN] LIPID COMPOSITIONS WITH HIGH DHA CONTENT<br/>[FR] COMPOSITIONS LIPIDIQUES À FORTE TENEUR EN DHA
  申请人：HALLARAKER HOGNE

  公开号：WO2013033618A1

  公开（公告）日：2013-03-07

  The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
• [EN] COMPOSITIONS FOR INCREASING STRENGTH, MUSCLE MASS, AND LEAN BODY MASS<br/>[FR] COMPOSITIONS DESTINÉES À AUGMENTER LA FORCE, LA MASSE MUSCULAIRE ET LA MASSE CORPORELLE MAIGRE
  申请人：DE FERRA LORENZO

  公开号：WO2013177458A1

  公开（公告）日：2013-11-28

  Phosphatidic acid, lyso-phosphatidic acid, and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachectic patients, as well as resistance training individuals, to improve nitrogen balance. The oral administration of phosphatidic acid as well as other actives described herein was found to increase muscle hypertrophy, strength, and lean body mass, and to decrease body fat in subjects, for example, when combined with resistance training.